eMC Medicine Guides  
The electronic Medicines Compendium (eMC) contains information about UK licensed medicines.
go to eMC homepage
Search for:  
  Advanced Search

Britannia Pharmaceuticals Limited
Park View House, 65 London Road, Newbury, Berkshire, RG14 1JN
Telephone: +44 (0) 1635 568 400
Fax: +44 (0) 1635 568 401
WWW: http://www.britannia-pharm.co.uk/
Medical Information Direct Line: +44 (0)870 851 0207
Medical Information e-mail: enquiries@medinformation.co.uk

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?
Summary of Product Characteristics last updated on the eMC: 15/09/2010
SPC BritLofex Tablets 0.2mg

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 15/09/2010 and displayed until Current
Reasons for adding or updating:
  • Change to MA holder contact details
Date of revision of text on the SPC:   29-Jun-2010
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company
Address change for marketing authorisation holder, Britannia Pharmaceuticals Ltd from Brighton Road to Park View House
Updated on 04/09/2009 and displayed until 15/09/2010
Reasons for adding or updating:
  • Improved Electronic Presentation
Date of revision of text on the SPC:   01-May-2009
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company
None provided
Updated on 19/09/2006 and displayed until 04/09/2009
Reasons for adding or updating:
  • Change to section 4.2 - Posology and Method of Administration
Date of revision of text on the SPC:   07/2006
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

There have been changes to the dosage of this medication in the following section:

 

-             Posology and Method of Administration:

 

The initial dose has been changed from “one 0.2mg tablet twice daily” to “0.8mg per day in divided doses”. The increments per day have changed from “0.2-0.4mg/day” to “0.4 to 0.8mg per day”. The maximum dose remains the same at 2.4mg/day.
Updated on 04/02/2005 and displayed until 19/09/2006
Reasons for adding or updating:
  • Change to section 6. 5 - Nature and Contents of Container
Updated on 23/09/2004 and displayed until 04/02/2005
Reasons for adding or updating:
  • Change to section 3 - pharmaceutical form
  • Change to section 4.2 - Posology and Method of Administration
  • Change to section 4.5 - Interactions with other Medicaments and other forms of Interaction
  • Change to section 5.1 - Pharmacodynamic Properties
  • Change to section 5.3 - Preclinical Safety Data
  • Change to section 6. 4 - Special Precautions for Storage
Updated on 23/09/2004 and displayed until 23/09/2004
Reasons for adding or updating:
  • Change to section 3 - pharmaceutical form
  • Change to section 4.2 - Posology and Method of Administration
  • Change to section 4.5 - Interactions with other Medicaments and other forms of Interaction
  • Change to section 5.1 - Pharmacodynamic Properties
  • Change to section 5.3 - Preclinical Safety Data
  • Change to section 6. 4 - Special Precautions for Storage
Updated on 23/09/2004 and displayed until 23/09/2004
Reasons for adding or updating:
  • Change to section 3 - pharmaceutical form
  • Change to section 4.2 - Posology and Method of Administration
  • Change to section 4.5 - Interactions with other Medicaments and other forms of Interaction
  • Change to section 5.1 - Pharmacodynamic Properties
  • Change to section 5.3 - Preclinical Safety Data
  • Change to section 6. 4 - Special Precautions for Storage
Updated on 13/06/2003 and displayed until 23/09/2004
Reasons for adding or updating:
  • Change to section 4.1 - Therapeutic Indications
  • Change to section 4.4 - Special Warnings and Precautions for Use
  • Change to section 4.5 - Interactions with other Medicaments and other forms of Interaction
Updated on 11/06/2003 and displayed until 13/06/2003
Reasons for adding or updating:
  • Change to section 4.4 - Special Warnings and Precautions for Use
  • Change to section 4.8 - Undesirable Effects
Updated on 24/08/2001 and displayed until 11/06/2003
Reasons for adding or updating:
  • Transferred from eMC version 1
Updated on 21/08/2001 and displayed until 24/08/2001
Reasons for adding or updating:
  • Change from datasheet to SPC

Active Ingredients/Generics

 
  lofexidine hydrochloride